AB MR Interpretation Overview

Similar documents
Leonard M. Glassman MD

BI-RADS Update. Martha B. Mainiero, MD, FACR, FSBI Brown University Rhode Island Hospital

Pitfalls and Limitations of Breast MRI. Susan Orel Roth, MD Professor of Radiology University of Pennsylvania

Imaging in breast cancer. Mammography and Ultrasound Donya Farrokh.MD Radiologist Mashhad University of Medical Since

BI-RADS and Breast MRI. Kathy Borovicka, M.D. Thursday February 15, 2018

MRI BI-RADS: How to make it out?

Breast Imaging Lexicon

Armed Forces Institute of Pathology.

Criteria of Malignancy. Evaluation Score

ACRIN 6666 IM Additional Evaluation: Additional Views/Targeted US

PLACE LABEL HERE. ACRIN 6657 MRI Form: Pre-Treatment (MRI-1)

Amammography report is a key component of the breast

PLACE LABEL HERE BASELINE / PRE-TREATMENT. ACRIN 6657 Extension MRI Form: Baseline / Pre-Treatment MRI 1. o Unknown

MRI in breast cancer: diagnosis and intervention. Dr Sue Barter Addenbrookes Hospital, Cambridge UK

Non-mass Enhancement on Breast MRI. Aditi A. Desai, MD Margaret Ann Mays, MD

Ana Sofia Preto 19/06/2013

UW Radiology Review Course Breast Calcifications. BI-RADS 5 th Edition

RSNA, /radiol Appendix E1. Methods

Radiologic and pathologic correlation of non-mass like breast lesions on US and MRI: Benign, high risk, versus malignant

Radiologic and pathologic correlation of non-mass like breast lesions on US and MRI: Benign, high risk, versus malignant

ORIGINAL ARTICLE EVALUATION OF BREAST LESIONS USING X-RAY MAMMOGRAM WITH HISTOPATHOLOGICAL CORRELATION

Index. C Calcifications fat necrosis 1, 61 fat necrosis 4, 69 nipple/peri-areolar involvement 1, 165

Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node

Breast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina

Mammographic imaging of nonpalpable breast lesions. Malai Muttarak, MD Department of Radiology Chiang Mai University Chiang Mai, Thailand

S. Murgo, MD. Chr St-Joseph, Mons Erasme Hospital, Brussels

Pathologic outcomes of coarse heterogeneous calcifications detected on mammography

of Thyroid Lesions Comet Tail Crystals

Benign, Reactive and Inflammatory Lesions of the Breast

Value of the BI-RADS classification in MR-Mammography for diagnosis of benign and malignant breast tumors

Essentials of Clinical MR, 2 nd edition. 73. Urinary Bladder and Male Pelvis

Tips and Tricks to performing Magnetic Resonance Imaging Guided Breast Interventional Procedures Habib Rahbar, MD, FSBI October 23, 2018, 7:00pm ET

Imaging the Symptomatic Patient. Avice M.O Connell MD,FACR,FSBI Professor of Imaging Sciences Director, Women s Imaging University of Rochester

National Diagnostic Imaging Symposium 2013 SAM - Breast MRI 1

Emerging Techniques in Breast Imaging: Contrast-Enhanced Mammography and Fast MRI

Leonard M. Glassman MD Analysis of Breast Calcifications

The Incidental Renal lesion

Contrast-enhanced Breast MRI RSSA 2013

Ductal carcinoma in situ: ultrasound, mammography and MRI features with pathologic correlation

Standard Breast Imaging Modalities. Lilian Wang, M.D. Breast Imaging Section Department of Radiology Northwestern Medicine

Triple-negative breast cancer: which typical features can we identify on conventional and MRI imaging?

8/31/2016 HIDING IN PLAIN SITE, ARCHITECTURAL DISTORTIONS AND BREAST ASYMMETRIES ARCHITECTURAL DISTORTIONS ARCHITECTURAL DISTORTIONS

OPTO-ACOUSTIC BREAST IMAGING

1 Uniform hyperintense signal intensity (normal). 2 Linear (arrow), wedge-shaped, or diffuse mild hypointensity, usually indistinct margin.

Case-based discussion:

BREAST MRI. VASILIKI FILIPPI RADIOLOGIST CT MRI & PET/CT Departments Hygeia Hospital, Athens, Greece

Thyroid Nodules: US Risk Stratification. Alex Tessnow, MD, FACE, ECNU University of Texas Southwestern Associate Professor of Medicine Dallas, Texas

Evolution of diagnostic ultrasound systems Current achievements in breast ultrasound

Breast Cancer Screening with Mammography

Breast calcification: Management and Pictorial Review

FIBROEPITHELIAL LESIONS

Pictorial Essay Singapore Med J 2009; 50(9) :

CDIS: what's beyond microcalcifications? - Pictorial essay

Benign breast lesions frequently encountered on MR

Endocrinology and Metabolic Disorder Unit Regina Apostolorum Hospital

MRI Occult Invasive Breast Cancer

Pitfalls of Dynamic Contrast Enhanced MR Mammography (DCE-MRM) in Evaluation of Post-Biopsy Suspicious Breast Lesions

MEDICAL IMAGING AND BREAST DISEASE HOW CAN WE HELP YOU?

Learning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening

Evaluation of BI-RADS 3 lesions in women with a high risk of hereditary breast cancer.

BI-RADS Categorization As a Predictor of Malignancy 1

Using T2-Weighted Sequences to More Accurately Characterize Breast Masses Seen on MRI

MRI features of Triple-negative breast cancer: our experience.

Thyroid in a Nutshell Dublin Catherine Kirkpatrick Consultant Sonographer ULHT

Diagnostic Dilemmas of Breast Imaging

AMSER Case of the Month: November 2018

University of Washington Radiology Review Course: Strange and Specific Diagnoses. Case #1

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

The radiologic workup of a palpable breast mass

Here are examples of bilateral analog mammograms from the same patient including CC and MLO projections.

Rate of Malignancy in MRI-Detected Probably Benign (BI-RADS 3) Lesions

Breast Cancer. Saima Saeed MD

ISSN X (Print) Research Article. *Corresponding author Dr. Amlendu Nagar

K. M. Sorensen Utah State University, Logan, Utah

Category Term Definition Comments 1 Major Categories 1a

BI-RADS MRI: A Primer

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

Hiding in Plain Sight / Site: Archictectural Distortions and Breast Asymmetries

DESCRIPTION: Percentage of final reports for screening mammograms that are classified as probably benign

Ultrasound of the Breast BASICS FOR THE ORDERING CLINICIAN

A GP S APPROACH TO BREAST LUMPS AND SYMPTOMS DR KK CHEUNG GPGC WORKSHOP

SIGNIFICANT OTHERS. Miscellaneous Benign Breast Conditions

Radiology Review Course Hotel del Coronado Coronado, California

DESCRIPTION: Percentage of final reports for screening mammograms that are classified as probably benign

Sonographic Features of Thyroid Nodules & Guidelines for Management

Screening with New Modalities: Breast Ultrasound

04/10/2018. Intraductal Papillary Neoplasms Of Breast INTRADUCTAL PAPILLOMA

Breast imaging of benign fat containing lesions

Breast Cancer Screening and Treatment Mrs Belinda Scott Breast Surgeon Breast Associates Auckland

Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006

Contents. Basic Ultrasound Principles and Terminology. Ultrasound Nodule Characteristics

11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.

THYROID NODULES: THE ROLE OF ULTRASOUND

Mousa. Israa Ayed. Abdullah AlZibdeh. 0 P a g e

Melissa Hartman, DO Women s Health Orlando VA Medical Center

OF HEMATOMA INTRACRANIAL HEMORRHAGE

Gynecomastia and Its Mimics: Not All Male Breast Lesions are Benign

3D Conformal Radiation Therapy for Mucinous Carcinoma of the Breast

First Clinical Experiences with Simultaneous Multi-Slice Accelerated Diffusion-Weighted Imaging Throughout the Body

Transcription:

AB MR Interpretation Overview Goal of AB MR interpretation is to maintain high sensitivity and specificity In order to minimize false positives and short term follow ups, it is fundamental to focus only on findings truly unique to the background parenchymal enhancement (BPE)

Approach to AB MR Interpretation Readout Review clinical history Assess image quality Subtraction MIPs (global assessment) Review of axial images linked: T1 pre, T1 post, subtractions, T2 Compare to prior mammograms, and ultrasounds

Classification of Unique Findings Focus Mass Non mass enhancement

Approach to Unique Focus on Baseline AB MR Focus should be a unique finding and distinct from the BPE. No other similar focus should be present elsewhere in that breast or in the contralateral breast. Biopsy and follow up reserved for focus 3 <5mm in size

Unique 3 <5 mm Focus on Baseline AB MR: Single, dominant INFLAMMATORY CYST (CENTRAL HIGH PRE T1 OR T2) CIRCUMSCRIBED MARGINS IRREGULAR SHAPE OR MARGINS BENIGN BX YES HIGH T2 NO BENIGN YES RIM ENHANCEMENT NO BX 6 MO FU

Approach to Unique Focus First step: Exclude small inflammatory cysts which are benign

Small Inflammatory Cyst Pre contrast T1 Post contrast T1 Pre contrast T1 image demonstrates a high T1 focus matching the central cavity on the post contrast image.

Approach to Unique Focus Next step: Evaluate margins Is it circumscribed or not circumscribed?

Unique 3 5 mm Focus on Baseline AB MR: Single, dominant CIRCUMSCRIBED MARGINS IRREGULAR SHAPE OR MARGINS NEED TO ASSESS ADDITIONAL FEATURES BX

Unique Focus Margins not circumscribed Biopsy Margins circumscribed Evaluate T2 signal

Circumscribed Unique Focus If there is a unique circumscribed focus, then evaluate T2 SI: High T2: Higher than normal gland, equivalent to cysts, blood vessels or lymph nodes Otherwise considered intermediate or low T2 When evaluating T2 images, window image appropriately to appreciate differences in signal intensity between fat, tissue, and fluid Cysts and blood vessels should be bright but not over saturated If window and level are set at too narrow of a range, then areas may falsely appear as being bright on T2 images

Unique 3 <5 mm Focus on Baseline AB MR: Single, dominant CIRCUMSCRIBED MARGINS YES HIGH T2? NO T1 POST T2 BENIGN NEED TO ASSESS ADDITIONAL FEATURES

Unique Circumscribed Focus NOT High on T2 If there is a circumscribed unique focus that is not high on T2 images, is there rim enhancement? Yes: Biopsy Rim enhancement is suspicious enough to warrant biopsy No: 6 month follow up

Unique 3 5 mm Focus on Baseline AB MR: Single, dominant CIRCUMSCRIBED MARGINS AND LOW OR INTERMEDIATE T2 YES RIM ENHANCEMENT NO BIOPSY 6 MONTH FOLLOW UP

Approach to Unique Mass

Unique Mass on Baseline AB MR NOT CIRCUMSCRIBED OR RIM ENHANCEMENT CIRCUMSCRIBED INFLAMMATORY CYST, DEGENERATED FIBROADENOMA, OR LYMPH NODE BX HIGH T2 NOT HIGHT2 BENIGN 6 MO FU HOMOGENEOUS ENHANCEMENT HETEROGENEOUS ENHANCEMENT 6 MO FU BX

Approach to Unique Mass Exclude classically benign masses: Inflammatory cysts Lymph nodes Degenerated fibroadenomas

Classically Benign Mass: Inflammatory Cyst Rim enhancing mass with a high signal correlate on pre contrast T1 or T2 weighted images Correlate must match in SIZE AND SHAPE to the inner cavity of the rim enhancement on the post contrast images Interface between the dark inner cavity and peripheral enhancement (inner wall) must be smooth

Classically Benign Mass: Inflammatory Cyst Post contrast T1 T2 The T2 fluid component matches the size and shape of the inner cavity on the postcontrast T1 image. Also, the interface between the inner cavity and peripheral enhancement in smooth

NOT Inflammatory Cyst (Rim enhancing mass) Post contrast T1 T2 Although there is a high correlate on the T2 weighted image, the high T2 correlate is smaller and does not match the central dark area on the post contrast T1 in terms of size and shape. The T2 correlate is smaller then the central cavity area on the post contrast images. This was a high grade IDC.

Classically Benign Mass: Lymph Node Intramammary lymph nodes are the following: Circumscribed Lobulated High on T2 weighted images Usually located superficially in the upper outer quadrant and commonly adjacent to blood vessels

Classically Benign Mass: Lymph Node Post contrast T1 T2

Classically Benign Mass: Degenerated Fibroadenoma Degenerated fibroadenoma Circumscribed Intermediate or low T2 signal Dark internal septations Low level enhancement (i.e. incomplete enhancement above a 50% threshold) Probably fibroadenoma on a baseline MR should be given a BI RADS 3. However, it is the low level partial enhancement that justifies a BI RADS 2 recommendation on a baseline AB MR

Classically Benign Mass: Degenerated Fibroadenoma Subtraction T2 Because the circumscribed, low T2 mass minimally and incompletely enhances, a BI RADS 2 recommendation is appropriate

Approach to Unique Mass Once classically benign masses (inflammatory cysts, lymph nodes, degenerated fibroadenomas) are excluded, evaluate margins: Circumscribed Assess other imaging features Not circumscribed OR rim enhancing Biopsy Any unique mass with non circumscribed margins or rim enhancement on a baseline AB MR must be biopsied

Unique Mass on Baseline AB MR NOT CIRCUMSCRIBED OR RIM ENHANCEMENT CIRCUMSCRIBED MARGINS BX NEED TO ASSESS ADDITIONAL FEATURES

Unique Rim Enhancing Mass Post contrast T1 T2 Rim enhancement on the post contrast T1 weighted images is within the area that is high on the T2 sequence. The high T2 signal does not match in size and shape to the dark central cavity on the post contrast T1 weighted image. This distinguishes a rim enhancing mass from an inflammatory cyst. Biopsy should be recommended for all rim enhancing masses, regardless of other imaging features (ie high T2 correlate and circumscribed margins).

Unique Circumscribed Mass If there is a unique circumscribed, NOT rim enhancing mass, the next step is to evaluate for a high T2 signal intensity correlate

Unique Mass on Baseline AB MR CIRCUMSCRIBED HIGH T2 NOT HIGH ON T2 T1 post T2 T1 post T2

Unique Mass on Baseline AB MR CIRCUMSCRIBED HIGH T2 NOT HIGH ON T2 Follow Up

Unique Circumscribed High T2 NON Rim Enhancing Mass Post contrast T1 T2 A 6 month follow up is appropriate for a circumscribed, high T2 homogeneously or heterogeneously enhancing mass on a baseline AB MR. Breast cancers that are high signal on T2 weighted images are unusual unless rim enhancement or irregular margins are present.

Unique Circumscribed, NOT Rim Enhancing High T2 Mass Presence of a high T2 signal correlate for a circumscribed unique, non rim enhancing mass is highly suggestive of a benign etiology If rim enhancing Biopsy If homogeneous or heterogeneous enhancement 6 month follow up

Unique Mass on Baseline AB MR CIRCUMSCRIBED HIGH T2 NOT HIGH ON T2 HOMOEGENEOUS ENHANCEMENT HETEROGENEOUS ENHANCEMENT Follow Up BX

Unique Circumscribed NOT High T2 Homogeneously Enhancing Mass Post contrast T1 T2 This is an example of a circumscribed homogeneously enhancing mass with thin dark internal septations that is not high signal intensity on the T2 weighted images. A 6 month follow up would be appropriate.

Unique Circumscribed NOT High T2 Heterogeneously Enhancing Mass This is an example of a circumscribed heterogeneously enhancing mass that is not high signal intensity on the T2 weighted images. Biopsy should be recommended for a circumscribed, NOT high T2 signal intensity mass with either heterogeneous or rim enhancement.

Unique Circumscribed Not Rim Enhancing Mass NOT High on T2 If there is a unique circumscribed, non rimenhancing mass that is not high on T2, management will depend on the internal enhancement pattern If heterogeneously enhancing Biopsy If homogeneously enhancing (can include thin non enhancing septations) 6 month follow up

Approach to NME

Unique Non Mass Enhancement on Baseline AB MR DISTRIBUTION: LINEAR, SEGMENTAL DISTRIBUTION: FOCAL, REGIONAL, MULTIPLE REGIONS, DIFFUSE BX INTERNAL ENHANCEMENT: CLUMPED HETEROGENEOUS CLUSTERED RING BX ASSOCIATED FIBROCYSTIC CHANGE ON T2 YES INTERNAL ENHANCEMENT: HOMOGENEOUS NO Benign 6 MO FU

Approach to Unique Non mass Enhancement Management depends on distribution and internal enhancement: Linear or segmental distribution Biopsy Clumped, heterogeneous, or Biopsy clustered ring

Suspicious NME Linear, clumped NME Segmental clumped and heterogeneous NME Multi regional clumped and heterogeneous NME

Probably Benign NME A 6 month follow up is appropriate for a focal area of NME that is not high signal intensity on the T2 weighted sequence.

Benign NME There is a focal area of NME with a high signal intensity correlate on the T2 weighted sequence. No biopsy or follow up is necessary.

Unique homogeneous NME NOT in a linear or segmental distribution Unique homogeneous NME is the least suspicious pattern of NME If there is a high T2 correlate, this likely represent focal fibrocystic change Benign If no high T2 correlate 6 month follow up